{
    "2018-09-20": [
        [
            {
                "time": "2018-09-24",
                "original_text": "Animal health firm Elanco surges 41 percent on debut",
                "features": {
                    "keywords": [
                        "Elanco",
                        "surges",
                        "debut"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "health",
                        "pharma"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-24",
                "original_text": "Eli Lilly Prices Animal Health Unit IPO at $24 Per Share",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "IPO",
                        "Animal Health",
                        "$24"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "health",
                        "pharma"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-24",
                "original_text": "Elanco Animal Health stock soars more than 35% in trading debut",
                "features": {
                    "keywords": [
                        "Elanco",
                        "soars",
                        "trading debut"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "health",
                        "pharma"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-24",
                "original_text": "Elanco CEO on IPO, animal health focus",
                "features": {
                    "keywords": [
                        "Elanco",
                        "CEO",
                        "IPO",
                        "animal health"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "health",
                        "pharma"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-24",
                "original_text": "Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates",
                "features": {
                    "keywords": [
                        "Pharma Stocks",
                        "GlaxoSmithKline",
                        "Revenue Trend",
                        "2018 Estimates"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharma"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-24",
                "original_text": "Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates",
                "features": {
                    "keywords": [
                        "Pharma Stocks",
                        "Allergan",
                        "Revenue Trend",
                        "2018 Estimates"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharma"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-24",
                "original_text": "Elanco’s $1.7 billion IPO looks too pricey, and here’s why",
                "features": {
                    "keywords": [
                        "Elanco",
                        "IPO",
                        "$1.7 billion",
                        "pricey"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "health",
                        "pharma"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-24",
                "original_text": "Elanco’s $1.6 billion IPO looks too pricey, and here’s why",
                "features": {
                    "keywords": [
                        "Elanco",
                        "IPO",
                        "$1.6 billion",
                        "pricey"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "health",
                        "pharma"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-24",
                "original_text": "D-Day Nearing For Antares Pharma",
                "features": {
                    "keywords": [
                        "D-Day",
                        "Antares Pharma"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharma"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}